Back to search

University of Patras

Διακρίβωσιη της γενετικής αιτιολογίας της ανταπόκρισης μεταμοσχευμένων ασθενών στην ανοσοκατασταλτική θεραπευτική αγωγή

Abstract

dc:description

Tacrolimus is one of the key factors of current immunosuppressive therapy following renal transplantation. The narrow therapeutic window of tacrolimus and its high pharmacokinetic variability renders dose selection challenging. Therefore, therapeutic drug monitoring (TDM) is used to direct tacrolimus dosing. However, tacrolimus pharmacokinetics are highly variable resulting in high or low blood trough tacrolimus concentrations associated with toxicity or graft rejection, respectively. The inter-individual diversity during the first-pass metabolism and clearance of tacrolimus is explained by genetic polymorphisms in enzymes involved in these processes. Alterations to genes involved in metabolism CYP3A4 and CYP3A5, to ABCB1 drug transporter and the regulatory genes POR and PXR, are the major heterogeneity factors in the response of the kidney transplant recipients to tacrolimus. The aim of the present retrospective study was to describe the frequency of functional SNPs of the above genes in Greek and Egyptian patients with renal transplantation. In addition, the contribution of these genetic variants to the pharmacokinetics of tacrolimus was investigated. The pharmacogenomic study involved 94 Greek and 76 Egyptian kidney transplant patients receiving immunosuppressive therapy with tacrolimus for at least 12 months. DNA was isolated from patients’ blood samples, followed by amplification by PCR and genotyping by either RFLP or Sanger sequencing. Demographic data as well as clinical characteristics of the patients were collected, including tacrolimus dosage and trough levels for a period of one year after transplantation. Statistical analysis of both genotypic and pharmacokinetic data was performed. The study confirmed the incidence of all studied polymorphisms in Caucasians and Africans, in both populations. CYP3A5 expressers require significantly higher tacrolimus doses compared to non-expressers in order to achieve the same therapeutic effect in both populations. Carriers of *1B and *22 alleles of CYP3A4 gene showed higher tacrolimus dose than CYP3A4*1/*1 in the maintenance treatment period. Reduction of the required tacrolimus dose was observed in all recipients regardless of the genotype of rs1045642 variant of ABCB1 gene. Carriers of *28 allele of POR gene received lower doses than patients with POR*1/*1 genotype. The same results were obtained for the carriers of rs3814055 polymorphic allele of PXR. The results of this first pharmacogenomic association study conducted in Greek and Egyptian populations show that rs776746, rs2740574, rs35599367, rs1045642, rs1057868 and rs3814055 are important determinants of tacrolimus disposal and may explain part of the clinically observed variability between individuals in tacrolimus pharmacokinetics. Thus, the prospective characterization of these genetic loci as well as their combination prior to kidney transplantation can provide important information on optimizing and personalizing immunosuppressive therapy for each candidate for renal graft.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mendrinou, Effrosyni
  • Μενδρινού, Ευφροσύνη

Subjects

dc:subject × 30

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49208

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mendrinou, Effrosyni; Μενδρινού, Ευφροσύνη. Διακρίβωσιη της γενετικής αιτιολογίας της ανταπόκρισης μεταμοσχευμένων ασθενών στην ανοσοκατασταλτική θεραπευτική αγωγή. University of Patras, 2021. http://hdl.handle.net/10442/hedi/49208